Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing

In a dose-ranging study of amprenavir (formerly 141W94), an inhibitor of th e protease enzyme of human immunodeficiency virus (HIV) type 1, single-dose and steady-state pharmacokinetic parameters were estimated from plasma sam ples collected on day 1 and during week 3, respectively. Amprenavir was adm inistered on either a twice-daily (b.i.d.) or three-times-daily dosage sche dule to 62 HIV-infected adults, 59 of whom had pharmacokinetic data. Log-lo g regression analysis (the power model) revealed that the steady-state area under the curve (AUC(ss)) and the maximum, minimum, and average concentrat ions at steady state (C-max,C-ss, C-min,C-ss, and C-avg,C-ss, respectively) increased in a dose-proportional manner over the 300- to 1,200-mg dose ran ge. Steady-state clearance was dose independent. AUC(ss)/AUC(0-->infinity) decreased linearly with dose and correlated significantly with treatment-as sociated decreases in alpha (1)-acid glycoprotein. After 3 weeks, the dose of 1,200 mg b.i.d. provided a median amprenavir C-min,C-ss (0.280 mug/ml) t hat was higher than the median in vitro 50% inhibitory concentration for cl inical HIV isolates (0.023 mug/ml), even after adjustment for protein bindi ng. The median amprenavir C-min,C-ss was also greater than the estimated in vivo trough concentration calculated to yield 90% of the maximum antiviral effect (0.228 mug/ml) over 4 weeks. A pharmacodynamic analysis of the rela tionship between steady-state pharmacokinetic parameters and safety reveale d headache and oral numbness to be the only side effects significantly asso ciated with C-max. The pharmacodynamic relationship defined in this study s upports the use of 1,200 mg b.i.d. as the approved dose of amprenavir.